<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>BioNixus blog</title>
    <link>https://www.bionixus.com/blog</link>
    <description>Healthcare and industry research articles from BioNixus.</description>
    <language>en</language>
    <lastBuildDate>Mon, 16 Nov 2026 19:58:07 GMT</lastBuildDate>
    <atom:link href="https://www.bionixus.com/blog/rss.xml" rel="self" type="application/rss+xml" />
<item>
  <title>The FDA Approved the First Drug for Adult Membranous Nephropathy. Coverage Comes Next</title>
  <link>https://www.bionixus.com/blog/gazyva-primary-membranous-nephropathy-fda-approval-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/gazyva-primary-membranous-nephropathy-fda-approval-2026</guid>
  <pubDate>Sun, 15 Nov 2026 09:48:00 GMT</pubDate>
  <description>The FDA approved Gazyva on 13 Nov 2026 as the first drug for primary membranous nephropathy. What US access teams should do next.</description>
</item>
<item>
  <title>Saudi hematology diagnostics reports count analyzers. Pharma still needs the ward-level brand cut</title>
  <link>https://www.bionixus.com/blog/saudi-hematology-diagnostics-vs-ward-brand-cut</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-hematology-diagnostics-vs-ward-brand-cut</guid>
  <pubDate>Sun, 15 Nov 2026 06:00:00 GMT</pubDate>
  <description>Saudi hematology diagnostics reports count lab products. Pharma still needs the ward-level brand cut a diagnostics total omits.</description>
</item>
<item>
  <title>Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching</title>
  <link>https://www.bionixus.com/blog/saudi-diabetes-syndicated-vs-hospital-switching</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-diabetes-syndicated-vs-hospital-switching</guid>
  <pubDate>Sun, 15 Nov 2026 05:45:00 GMT</pubDate>
  <description>Saudi diabetes category totals miss which hospital is switching. Primary research is what a launch team still has to answer.</description>
</item>
<item>
  <title>ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant</title>
  <link>https://www.bionixus.com/blog/adcan-pharma-m42-uae-oncology-manufacturing-clinical-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/adcan-pharma-m42-uae-oncology-manufacturing-clinical-research</guid>
  <pubDate>Wed, 11 Nov 2026 08:00:00 GMT</pubDate>
  <description>ADCAN Pharma and M42&apos;s UAE oncology MoU starts with packaging and registration, not an ADC plant. What pharma teams should research.</description>
</item>
<item>
  <title>The UAE Has Cleared Lilly&apos;s Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now</title>
  <link>https://www.bionixus.com/blog/lilly-foundayo-orforglipron-uae-type-2-diabetes-approval</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/lilly-foundayo-orforglipron-uae-type-2-diabetes-approval</guid>
  <pubDate>Tue, 10 Nov 2026 08:00:00 GMT</pubDate>
  <description>The UAE approved Lilly&apos;s oral GLP-1 Foundayo for type 2 diabetes on 6 Nov 2026. What is confirmed, what is not, and what launch teams should research.</description>
</item>
<item>
  <title>Novo Nordisk Gives Ozempic a Second Name, Plosbrio, and Hands It to Abbott in Asia Pacific</title>
  <link>https://www.bionixus.com/blog/novo-abbott-plosbrio-semaglutide-second-brand-asia-pacific</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/novo-abbott-plosbrio-semaglutide-second-brand-asia-pacific</guid>
  <pubDate>Mon, 09 Nov 2026 10:05:00 GMT</pubDate>
  <description>Abbott will sell Plosbrio, Novo Nordisk&apos;s second semaglutide brand, in Singapore and Asia Pacific for type 2 diabetes. What is confirmed, what is not, and what it means for GLP-1 markets.</description>
</item>
<item>
  <title>AstraZeneca Brings CRISPR Gene-Editing Research to Saudi Arabia: What the KAIMRC Programme Is, and Is Not</title>
  <link>https://www.bionixus.com/blog/astrazeneca-kaimrc-crispr-saudi-gene-editing-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/astrazeneca-kaimrc-crispr-saudi-gene-editing-research</guid>
  <pubDate>Mon, 09 Nov 2026 10:00:00 GMT</pubDate>
  <description>AstraZeneca and KAIMRC are running preclinical CRISPR research on ASL deficiency in Saudi Arabia, with training for up to 12 Saudi scientists. What is confirmed and what to research next.</description>
</item>
<item>
  <title>Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One</title>
  <link>https://www.bionixus.com/blog/avalon-pharma-onesource-saudi-generic-tirzepatide-glp1-market</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/avalon-pharma-onesource-saudi-generic-tirzepatide-glp1-market</guid>
  <pubDate>Thu, 05 Nov 2026 10:00:00 GMT</pubDate>
  <description>Avalon Pharma licensed a generic Mounjaro KwikPen (tirzepatide) from OneSource for Saudi Arabia and MENA. What it means for GLP-1 and obesity teams.</description>
</item>
<item>
  <title>Opella Launches Telfast Kids in the UAE Through 200 Doctors and Pharmacists. What It Tells Consumer Health Teams About Paediatric Allergy</title>
  <link>https://www.bionixus.com/blog/opella-telfast-kids-uae-paediatric-allergy-market</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/opella-telfast-kids-uae-paediatric-allergy-market</guid>
  <pubDate>Wed, 04 Nov 2026 17:10:00 GMT</pubDate>
  <description>Opella launched Telfast Kids in the UAE with the Emirates Pediatric &amp; Neonatal Society and about 200 doctors and pharmacists. What it means for OTC antihistamine and consumer health teams in the GCC.</description>
</item>
<item>
  <title>EVA Pharma&apos;s TriGutirek XR Puts a Triple Diabetes Tablet into Saudi Pharmacies. Here Is What Market Access Teams Should Check Next</title>
  <link>https://www.bionixus.com/blog/eva-pharma-trigutirek-xr-saudi-diabetes-market-access</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/eva-pharma-trigutirek-xr-saudi-diabetes-market-access</guid>
  <pubDate>Wed, 04 Nov 2026 17:05:00 GMT</pubDate>
  <description>EVA Pharma&apos;s TriGutirek XR (empagliflozin/linagliptin/metformin XR) is described as the first triple FDC of these actives approved in Saudi Arabia. Cigalah and United Pharmacies deals, SFDA listing notes, and what.</description>
</item>
<item>
  <title>Roche and Abu Dhabi&apos;s DoH Are Building Local Evidence on Diabetic Macular Edema. Here Is What That Means for UAE Diabetes Care Research</title>
  <link>https://www.bionixus.com/blog/roche-doh-abu-dhabi-dme-uae-diabetes-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/roche-doh-abu-dhabi-dme-uae-diabetes-market-research</guid>
  <pubDate>Wed, 04 Nov 2026 17:00:00 GMT</pubDate>
  <description>DoH Abu Dhabi and Roche Pharmaceuticals UAE announced a real-world evidence programme on diabetic macular edema. What commercial and market research teams should track next.</description>
</item>
<item>
  <title>Chinese visitors to the Gulf rose last year, and boards still lack spend data</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/chinese-tourists-dubai-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/chinese-tourists-dubai-research</guid>
  <pubDate>Sun, 01 Nov 2026 19:00:00 GMT</pubDate>
  <description>Chinese tourist research for Dubai and the Gulf: Saudi arrivals rose 48% in 2025, Dubai has not published a 2026 China split, and what to ask visitors.</description>
</item>
<item>
  <title>Chinese suppliers are winning Saudi giga-project work, and the buyers sit with a few teams</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/chinese-suppliers-saudi-giga-projects-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/chinese-suppliers-saudi-giga-projects-research</guid>
  <pubDate>Sun, 01 Nov 2026 18:00:00 GMT</pubDate>
  <description>B2B research for Chinese suppliers on Saudi giga-projects: who decides after the Qiddiya award, local content scores, and how to interview the buyer group.</description>
</item>
<item>
  <title>Chinese phone brands are splitting in the Gulf, and shipment data cannot say why</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/brand-tracking-chinese-electronics-brands-middle-east</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/brand-tracking-chinese-electronics-brands-middle-east</guid>
  <pubDate>Sun, 01 Nov 2026 13:00:00 GMT</pubDate>
  <description>Brand tracking for Chinese phone and electronics brands in the Middle East: what Omdia shipment data misses, and how to track Gulf buyer awareness and NPS.</description>
</item>
<item>
  <title>Gulf health systems are investing in fertility care, and drugmakers lack data on what women need</title>
  <link>https://www.bionixus.com/blog/womens-health-market-research-gcc</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/womens-health-market-research-gcc</guid>
  <pubDate>Sun, 01 Nov 2026 12:00:00 GMT</pubDate>
  <description>Women’s health market research in the GCC: new fertility deals, PCOS in Thiqa obesity cover and low menopause therapy use. What to ask doctors and patients.</description>
</item>
<item>
  <title>Singapore is the easy part of entering Southeast Asia, and the research starts at the border</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/market-entry-research-singapore-southeast-asia</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/market-entry-research-singapore-southeast-asia</guid>
  <pubDate>Sun, 01 Nov 2026 12:00:00 GMT</pubDate>
  <description>Market entry research for Singapore and Southeast Asia: why a Singapore base is not a proxy for Indonesia or Vietnam, and what to check in each market.</description>
</item>
<item>
  <title>Most Saudi adults with a mental disorder get no treatment, and CNS teams lack prescriber data</title>
  <link>https://www.bionixus.com/blog/mental-health-market-research-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/mental-health-market-research-saudi-arabia</guid>
  <pubDate>Sun, 01 Nov 2026 11:00:00 GMT</pubDate>
  <description>Mental health market research in Saudi Arabia: an 86% treatment gap, telepsychiatry and stigma. What CNS teams should ask psychiatrists and GPs at launch.</description>
</item>
<item>
  <title>Japanese drug and diagnostics makers are entering the Gulf through partners and factories</title>
  <link>https://www.bionixus.com/blog/japanese-pharmaceutical-companies-middle-east-entry</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/japanese-pharmaceutical-companies-middle-east-entry</guid>
  <pubDate>Sun, 01 Nov 2026 09:00:00 GMT</pubDate>
  <description>How Japanese pharmaceutical companies enter the Middle East: Kyorin’s nine-country partner deal, Sysmex’s Saudi factory plan, and the research to run first.</description>
</item>
<item>
  <title>Kuwait now sets a ceiling price for every medicine in its private market</title>
  <link>https://www.bionixus.com/blog/kuwait-drug-pricing-2026-decision-62</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/kuwait-drug-pricing-2026-decision-62</guid>
  <pubDate>Sun, 01 Nov 2026 09:00:00 GMT</pubDate>
  <description>Kuwait drug pricing under Decision 62/2026: one ceiling price per medicine, GCC reference checks and capped margins. What launch teams must prove first.</description>
</item>
<item>
  <title>The UAE is making drugs cheaper to distribute and stricter to monitor</title>
  <link>https://www.bionixus.com/blog/uae-pharmacovigilance-requirements-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/uae-pharmacovigilance-requirements-2026</guid>
  <pubDate>Sun, 01 Nov 2026 09:00:00 GMT</pubDate>
  <description>UAE pharmacovigilance requirements in 2026: EDE’s updated guideline on QPPV approval, RMPs, PSURs and patient programmes, plus the new 3PL storage route.</description>
</item>
<item>
  <title>Egypt Drug Prices in 2026: Dr. Mohammad Alsaadany on Decree 480, the Dollar and Supply</title>
  <link>https://www.bionixus.com/blog/egypt-drug-prices-2026-alsaadany-doctor-news</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/egypt-drug-prices-2026-alsaadany-doctor-news</guid>
  <pubDate>Mon, 26 Oct 2026 17:46:41 GMT</pubDate>
  <description>Dr. Mohammad Alsaadany on Al Shams TV: why the EDA can&apos;t force production at a loss, how Decree 480 pricing works, and why increases may stay near 10, 11%.</description>
</item>
<item>
  <title>أسعار الدواء في مصر 2026: د. محمد السعدني يشرح القرار 480 وأثر الدولار على السوق</title>
  <link>https://www.bionixus.com/blog/egypt-drug-prices-2026-alsaadany-doctor-news-ar</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/egypt-drug-prices-2026-alsaadany-doctor-news-ar</guid>
  <pubDate>Mon, 26 Oct 2026 17:46:41 GMT</pubDate>
  <description>د. محمد السعدني على قناة الشمس: لماذا لا تجبر هيئة الدواء الشركات على الإنتاج بخسارة، وكيف تعمل معادلة القرار 480، ولماذا قد لا تتجاوز الزيادات 10, 11%.</description>
</item>
<item>
  <title>EDA Decree 480/2026: How Egypt&apos;s New Drug Pricing Rules Change Launch, Generic and Account Strategy</title>
  <link>https://www.bionixus.com/blog/egypt-eda-decree-480-drug-pricing-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/egypt-eda-decree-480-drug-pricing-2026</guid>
  <pubDate>Fri, 23 Oct 2026 12:00:00 GMT</pubDate>
  <description>Egypt&apos;s EDA Decree 480/2026 links repricing to FX, inflation and rates, sets a 15-country basket and a generic ladder. What commercial teams should plan.</description>
</item>
<item>
  <title>ORZEYFUL (oveporexton) Launches in Japan and China: What a First-in-Class Sleep Medicine Teaches APAC Launch Teams</title>
  <link>https://www.bionixus.com/blog/orzeyful-oveporexton-narcolepsy-japan-china-launch-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/orzeyful-oveporexton-narcolepsy-japan-china-launch-2026</guid>
  <pubDate>Thu, 22 Oct 2026 12:00:00 GMT</pubDate>
  <description>Takeda launched ORZEYFUL (oveporexton) for narcolepsy type 1 in Japan and China. What the Japan NHI price file and labels mean for APAC launch planning.</description>
</item>
<item>
  <title>Gazya for Lupus in Brazil: What Anvisa&apos;s New Indication Means for Access, Accounts and Prescribers</title>
  <link>https://www.bionixus.com/blog/gazya-obinutuzumab-lupus-anvisa-brazil-access-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/gazya-obinutuzumab-lupus-anvisa-brazil-access-2026</guid>
  <pubDate>Wed, 21 Oct 2026 12:00:00 GMT</pubDate>
  <description>Anvisa approved Gazya (obinutuzumab) for active SLE on 13 Oct 2026. How CONITEC, ANS coverage rules and rheumatology accounts shape access in Brazil.</description>
</item>
<item>
  <title>DKSH to Acquire NewBridge Pharmaceuticals: What It Means for Oncology and Rare Disease Launches Across 14 MENA Markets</title>
  <link>https://www.bionixus.com/blog/dksh-newbridge-acquisition-mena-launch-market-access</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/dksh-newbridge-acquisition-mena-launch-market-access</guid>
  <pubDate>Tue, 20 Oct 2026 08:00:00 GMT</pubDate>
  <description>DKSH agreed to acquire NewBridge Pharmaceuticals for USD 390 million. What the deal means for oncology and rare disease launch and market access planning across 14 MENA markets.</description>
</item>
<item>
  <title>Rasonque (daraxonrasib) in Europe: What the CHMP Opinion Means for Pancreatic Cancer Launch Teams</title>
  <link>https://www.bionixus.com/blog/rasonque-daraxonrasib-pancreatic-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/rasonque-daraxonrasib-pancreatic-ema-chmp-2026</guid>
  <pubDate>Mon, 19 Oct 2026 12:00:00 GMT</pubDate>
  <description>CHMP backed Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer after a phased review. What EU launch and access teams should plan.</description>
</item>
<item>
  <title>China wants to stop foreign buyers taking its critical biotech platforms</title>
  <link>https://www.bionixus.com/blog/china-biotech-export-controls-pharma-deals-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/china-biotech-export-controls-pharma-deals-2026</guid>
  <pubDate>Sun, 18 Oct 2026 12:00:00 GMT</pubDate>
  <description>China biotech export controls, 16 Oct 2026: 40 AI, biotech and solar items. What BD and Gulf access teams should do by 15 Nov.</description>
</item>
<item>
  <title>The Medicare GLOBE Model: What Part B Brand Teams Need to Know Before 2027</title>
  <link>https://www.bionixus.com/blog/medicare-globe-model-part-b-account-level-2027</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/medicare-globe-model-part-b-account-level-2027</guid>
  <pubDate>Sun, 18 Oct 2026 12:00:00 GMT</pubDate>
  <description>The Medicare GLOBE Model ties some Part B rebates to prices in 19 countries, but only in areas covering about 25% of Original Medicare. What to plan now.</description>
</item>
<item>
  <title>ADCs, Bispecifics and CAR-T in Saudi Arabia: Researching Tertiary-Centre Adoption</title>
  <link>https://www.bionixus.com/blog/car-t-saudi-arabia-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/car-t-saudi-arabia-market-research</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>CAR-T Saudi Arabia market research for ADC and bispecific adoption at KFSHRC and KAMC: centre capacity, P-T and listed vials a 2026 brief must measure.</description>
</item>
<item>
  <title>Chinese Companies in Egypt: What to Research First</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/chinese-companies-egypt-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/chinese-companies-egypt-market-research</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>Plain steps for Chinese companies entering Egypt: who buys, which city, the price after 14% VAT, and which licence to use before you send money from China.</description>
</item>
<item>
  <title>Diabetes Market Research in the UAE After the 2026 Price Cuts</title>
  <link>https://www.bionixus.com/blog/diabetes-market-research-uae-2026-price-cuts</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/diabetes-market-research-uae-2026-price-cuts</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>Diabetes market research UAE after the 2026 EDE list cuts: what brand teams should commission on price, switching, pharmacy behaviour and payer listing.</description>
</item>
<item>
  <title>Dubai Essential Drug List (DEDL): How to Build the Evidence for a Formulary Listing</title>
  <link>https://www.bionixus.com/blog/dubai-essential-drug-list-formulary-submission</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/dubai-essential-drug-list-formulary-submission</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>Dubai Essential Drug List formulary submission: what DDC coding, EBP formulary limits and local evidence an affiliate should commission before listing.</description>
</item>
<item>
  <title>Market research in New Zealand for exporters targeting the GCC</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/new-zealand-exporters-gcc-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/new-zealand-exporters-gcc-market-research</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>New Zealand exporters GCC market research for dairy and meat: Saudi and UAE demand, CEPA, SFDA lists, MPI halal and VAT before a first Gulf container.</description>
</item>
<item>
  <title>Private Insurance Payer Research in Saudi Arabia: CHI, Insurers and Formulary Decisions</title>
  <link>https://www.bionixus.com/blog/saudi-health-insurance-payer-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-health-insurance-payer-research</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>Saudi health insurance payer research on CHI, the Dhaman formulary and insurer lists: what a 2026 launch team must commission before a private claim pays.</description>
</item>
<item>
  <title>UK market entry research: a guide for GCC and US companies</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/uk-market-entry-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/uk-market-entry-research</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>UK market entry research for GCC and US companies: four nations, 20% VAT, UKCA or CE, Companies House and price before a Riyadh or Dubai committee commits.</description>
</item>
<item>
  <title>US Market Entry Research for Middle East, European and Brazilian Companies</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/us-market-entry-research-for-foreign-companies</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/us-market-entry-research-for-foreign-companies</guid>
  <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
  <description>US market entry research for foreign companies: CFIUS, 50-state sales tax, FDA and price before a Riyadh, Dubai, London or Brazilian committee commits.</description>
</item>
<item>
  <title>Australian Exporters&apos; Guide to Saudi and UAE Market Research</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/australia-gcc-market-entry-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/australia-gcc-market-entry-research</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>Australia GCC market entry research playbook for exporters: prove demand, CEPA tariffs, cities, halal and price in Saudi Arabia and UAE before you ship.</description>
</item>
<item>
  <title>Chinese companies entering Saudi Arabia and the UAE: market research playbook</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/chinese-companies-entering-saudi-arabia-and-the-uae</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/chinese-companies-entering-saudi-arabia-and-the-uae</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>Chinese companies entering Saudi Arabia and the UAE need demand, licence, city and channel proof before a mainland HQ remits capital. A 2026 playbook.</description>
</item>
<item>
  <title>Chinese EV Brands in the Gulf: Consumer Research Before Launch</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/chinese-ev-brands-saudi-uae-consumer-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/chinese-ev-brands-saudi-uae-consumer-research</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>Chinese EV consumer research for Chinese EV brands in the Gulf: what Saudi and UAE teams must test on charging, TCO and aftersales before a 2026 launch.</description>
</item>
<item>
  <title>Europe-to-GCC market entry research: what European brands need to know</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/europe-to-gcc-market-entry-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/europe-to-gcc-market-entry-research</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>Europe-to-GCC market entry research for European brands: six-country sequencing, VAT, G-Mark, channels and price before a brand committee commits capital.</description>
</item>
<item>
  <title>Launching a drug in the UAE after the EDE takeover: pricing, repricing and the research behind them</title>
  <link>https://www.bionixus.com/blog/uae-drug-pricing-ede-takeover-launch-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/uae-drug-pricing-ede-takeover-launch-research</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>UAE drug pricing after the Emirates Drug Establishment takeover: what launch research must prove for first price, May 2026 repricing and payer listing.</description>
</item>
<item>
  <title>NUPCO Tenders in Saudi Arabia: What Market Research an Oncology or Specialty Bid Needs (2026)</title>
  <link>https://www.bionixus.com/blog/nupco-tender-market-research-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/nupco-tender-market-research-saudi-arabia</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>NUPCO tender market research for Saudi oncology and specialty bids: what vial lists, award ranks and centre facts a 2026 bid team must commission first.</description>
</item>
<item>
  <title>Oral GLP-1s in the UAE: Researching Prescriber and Patient Uptake of Orforglipron</title>
  <link>https://www.bionixus.com/blog/oral-glp-1-uae-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/oral-glp-1-uae-market-research</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>Oral GLP-1 UAE market research after EDE approved Foundayo on 3 Apr 2026: what brand teams must measure on orforglipron prescriber and patient uptake.</description>
</item>
<item>
  <title>Rare Disease Market Research in Saudi Arabia: Small Populations, Big Evidence Gaps</title>
  <link>https://www.bionixus.com/blog/rare-disease-market-research-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/rare-disease-market-research-saudi-arabia</guid>
  <pubDate>Fri, 16 Oct 2026 12:00:00 GMT</pubDate>
  <description>Rare disease market research Saudi Arabia: how to size small orphan populations, close evidence gaps, and brief SFDA, NUPCO and CHI before a 2026 launch.</description>
</item>
<item>
  <title>Government Customer Satisfaction Research in Saudi Arabia: Vision 2030 Service Quality</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/government-customer-satisfaction-research-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/government-customer-satisfaction-research-saudi-arabia</guid>
  <pubDate>Thu, 15 Oct 2026 16:00:00 GMT</pubDate>
  <description>Government customer satisfaction survey Saudi Arabia: Vision 2030, DGA CSAT, Absher/Tawakkalna, Arabic fieldwork and citizen satisfaction research KSA.</description>
</item>
<item>
  <title>B2B Market Research in the UAE: Reaching Hard-to-Reach Decision-Makers</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/b2b-market-research-uae</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/b2b-market-research-uae</guid>
  <pubDate>Thu, 15 Oct 2026 12:00:00 GMT</pubDate>
  <description>B2B market research UAE for hard-to-reach buyers: methods, recruitment, costs, and how to choose a B2B market research company Dubai. Named-sample 2026.</description>
</item>
<item>
  <title>Consumer Survey Research in Saudi Arabia: Sampling, Language and Mode</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/consumer-survey-company-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/consumer-survey-company-saudi-arabia</guid>
  <pubDate>Thu, 15 Oct 2026 12:00:00 GMT</pubDate>
  <description>Consumer survey company Saudi Arabia guide to sampling, Arabic/English, online vs CATI/F2F, women respondents, regions, costs and how to choose a firm.</description>
</item>
<item>
  <title>How to Choose a Healthcare Market Research Agency in Saudi Arabia: 10 Questions to Ask</title>
  <link>https://www.bionixus.com/blog/how-to-choose-healthcare-market-research-agency-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/how-to-choose-healthcare-market-research-agency-saudi-arabia</guid>
  <pubDate>Thu, 15 Oct 2026 12:00:00 GMT</pubDate>
  <description>Ten questions to ask a healthcare market research agency Saudi Arabia: field office, PDPL, SFDA, NUPCO, CHI panels, and what BioNixus puts in writing.</description>
</item>
<item>
  <title>Kantar Alternative Middle East: What Buyers Should Compare, and When a Specialist Fits Better</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/kantar-alternative-middle-east</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/kantar-alternative-middle-east</guid>
  <pubDate>Thu, 15 Oct 2026 12:00:00 GMT</pubDate>
  <description>Kantar alternative Middle East for custom research: what GCC buyers should compare, when a specialist market research agency alternative GCC fits better.</description>
</item>
<item>
  <title>Keep IQVIA, Add Primary Research: How UAE Brand Teams Combine Syndicated and Custom Data</title>
  <link>https://www.bionixus.com/blog/iqvia-alternative-uae-primary-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/iqvia-alternative-uae-primary-research</guid>
  <pubDate>Thu, 15 Oct 2026 12:00:00 GMT</pubDate>
  <description>IQVIA alternative UAE primary research for brand teams that keep syndicated audits and add custom physician, payer and patient studies from a Dubai office.</description>
</item>
<item>
  <title>Syndicated Retail Measurement vs Custom Primary Research in Saudi Arabia: When Each Fits and How to Combine Them</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/nielsen-alternative-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/nielsen-alternative-saudi-arabia</guid>
  <pubDate>Thu, 15 Oct 2026 12:00:00 GMT</pubDate>
  <description>Nielsen alternative Saudi Arabia: syndicated vs custom research Saudi Arabia, when a retail audit fits, when custom work is needed, how to combine both.</description>
</item>
<item>
  <title>Thiqa&apos;s Obesity Drug Policy Explained: What It Means for GLP-1 Demand in Abu Dhabi</title>
  <link>https://www.bionixus.com/blog/thiqa-obesity-reimbursement-abu-dhabi</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/thiqa-obesity-reimbursement-abu-dhabi</guid>
  <pubDate>Thu, 15 Oct 2026 12:00:00 GMT</pubDate>
  <description>Thiqa obesity reimbursement and Abu Dhabi GLP-1 coverage: DOH BMI gates, 5% weight-loss rules, and what obesity market research UAE must measure in 2026.</description>
</item>
<item>
  <title>Brand Tracking in Dubai and the UAE: Building a Tracker That Moves Budgets</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/brand-tracking-research-agency-dubai</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/brand-tracking-research-agency-dubai</guid>
  <pubDate>Tue, 13 Oct 2026 12:00:00 GMT</pubDate>
  <description>Brand tracking research agency Dubai guide: custom tracker vs syndicated data, bilingual UAE fieldwork from a Dubai field office, KPIs that move budgets.</description>
</item>
<item>
  <title>Market Entry Research for Saudi Arabia: A Non-Pharma Playbook</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/market-entry-research-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/market-entry-research-saudi-arabia</guid>
  <pubDate>Tue, 13 Oct 2026 12:00:00 GMT</pubDate>
  <description>Market entry research Saudi Arabia playbook for US, UK and European firms: demand, MISA registration, cities, channels and price before you commit capital.</description>
</item>
<item>
  <title>Qatar&apos;s GLP-1 Moment: Wegovy, Oral GLP-1 Approval and What to Research Next</title>
  <link>https://www.bionixus.com/blog/qatar-obesity-glp1-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/qatar-obesity-glp1-market-research</guid>
  <pubDate>Tue, 13 Oct 2026 12:00:00 GMT</pubDate>
  <description>Qatar obesity GLP-1 market research after Wegovy and MOPH oral GLP-1 approval: what STEPS, HMC cover and private prices mean for 2026 brand-team studies.</description>
</item>
<item>
  <title>Sickle Cell, Thalassemia and Gene Therapy in Saudi Arabia: What Pharma Needs to Research Before Launch</title>
  <link>https://www.bionixus.com/blog/hematology-market-research-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/hematology-market-research-saudi-arabia</guid>
  <pubDate>Tue, 13 Oct 2026 12:00:00 GMT</pubDate>
  <description>Hematology market research Saudi Arabia for sickle cell, thalassemia and Casgevy: what pharma must study before a 2026 launch, with sourced access facts.</description>
</item>
<item>
  <title>Kuwait Obesity Research: Who Funds GLP-1s and What Payers Need to See</title>
  <link>https://www.bionixus.com/blog/obesity-market-research-kuwait</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/obesity-market-research-kuwait</guid>
  <pubDate>Mon, 12 Oct 2026 15:00:00 GMT</pubDate>
  <description>Obesity market research Kuwait: who funds GLP-1s, what MOH and private payers need to see, and how BioNixus designs 2026 access studies for brand teams.</description>
</item>
<item>
  <title>Customer Satisfaction Surveys in the UAE: CSAT, NPS and CES Done Right</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/customer-satisfaction-surveys-uae-csat-nps-ces</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/customer-satisfaction-surveys-uae-csat-nps-ces</guid>
  <pubDate>Mon, 12 Oct 2026 12:00:00 GMT</pubDate>
  <description>Customer satisfaction survey company UAE guide to CSAT, NPS and CES, how an NPS survey company Saudi Arabia brief should specify the recommend question.</description>
</item>
<item>
  <title>Feasibility Studies in Saudi Arabia: What the Market Section Must Prove</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/feasibility-study-company-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/feasibility-study-company-saudi-arabia</guid>
  <pubDate>Mon, 12 Oct 2026 12:00:00 GMT</pubDate>
  <description>Feasibility study company Saudi Arabia: what the 2026 market section must prove, demand, price, channels, competition and SIDF-ready primary evidence.</description>
</item>
<item>
  <title>What Saudi Physicians Say About GLP-1s: Designing a GLP-1 Prescriber Survey in KSA</title>
  <link>https://www.bionixus.com/blog/glp-1-physician-survey-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/glp-1-physician-survey-saudi-arabia</guid>
  <pubDate>Mon, 12 Oct 2026 12:00:00 GMT</pubDate>
  <description>How to design a GLP-1 physician survey Saudi Arabia brand teams can act on: published KAP findings, specialty quotas, and BioNixus 3,200-physician reach.</description>
</item>
<item>
  <title>Who Does Obesity Market Research in Saudi Arabia? A 2026 Shortlist</title>
  <link>https://www.bionixus.com/blog/who-does-obesity-market-research-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/who-does-obesity-market-research-saudi-arabia</guid>
  <pubDate>Mon, 12 Oct 2026 12:00:00 GMT</pubDate>
  <description>Who does obesity market research in Saudi Arabia? A sourced 2026 shortlist of 8 providers for obesity GLP-1 market research Saudi Arabia teams can act on.</description>
</item>
<item>
  <title>Obesity Drug Market Share 2026: New GLP-1 Products, Lilly vs Novo Nordisk, and the B2B/B2C Research Behind the Race</title>
  <link>https://www.bionixus.com/blog/obesity-drug-market-share-glp-1-competition-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/obesity-drug-market-share-glp-1-competition-2026</guid>
  <pubDate>Mon, 05 Oct 2026 19:30:00 GMT</pubDate>
  <description>Obesity drug market share 2026: Zepbound vs Wegovy, Wegovy pill vs Foundayo, generics and pipeline, plus how BioNixus runs B2B and B2C obesity market research.</description>
</item>
<item>
  <title>UAE Healthcare Market Trends 2026: Payer, Specialty, and Access Shifts</title>
  <link>https://www.bionixus.com/blog/uae-healthcare-market-trends-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/uae-healthcare-market-trends-2026</guid>
  <pubDate>Mon, 31 Aug 2026 09:00:00 GMT</pubDate>
  <description>UAE healthcare trends 2026: payer tightening, DHA vs DOH access, specialty and biosimilars, and digital-health signals for pharma and medtech. BioNixus.</description>
</item>
<item>
  <title>China Device VBP Rounds Explained 2026: Price Cuts, Volume Commitments &amp; Localization</title>
  <link>https://www.bionixus.com/blog/china-device-vbp-rounds-explained</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/china-device-vbp-rounds-explained</guid>
  <pubDate>Tue, 18 Aug 2026 10:00:00 GMT</pubDate>
  <description>How China’s medical device Volume-Based Procurement works in 2026: stent and joint price-cut examples, win vs lose outcomes, renewals, and private-hospital escape valves.</description>
</item>
<item>
  <title>NMPA Class III Registration Timeline 2026: CMDE Review, Clinical Evidence &amp; Resident Agent</title>
  <link>https://www.bionixus.com/blog/nmpa-class-iii-registration-timeline-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/nmpa-class-iii-registration-timeline-2026</guid>
  <pubDate>Tue, 18 Aug 2026 09:00:00 GMT</pubDate>
  <description>NMPA Class III medical device registration in China 2026: CMDE review steps, clinical evaluation options, Resident Agent duties, and 18, 36 month planning benchmarks.</description>
</item>
<item>
  <title>BioNixus Wood Boards Manufacturing Market Research Trackers: Leading Across the Middle East and Africa</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/mdf-wood-manufacturing-market-research-trackers-mea</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/mdf-wood-manufacturing-market-research-trackers-mea</guid>
  <pubDate>Wed, 12 Aug 2026 20:37:54 GMT</pubDate>
  <description>Wood boards manufacturing market research trackers across the Middle East and Africa, pricing, demand and competitive signals.</description>
</item>
<item>
  <title>MedTech in Singapore 2026: Market Size, HSA Registration &amp; Key Players</title>
  <link>https://www.bionixus.com/blog/medtech-singapore-2026-market-hsa-registration</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/medtech-singapore-2026-market-hsa-registration</guid>
  <pubDate>Wed, 22 Jul 2026 09:00:00 GMT</pubDate>
  <description>Singapore&apos;s medtech industry in 2026, manufacturing scale, HSA Class A, D registration, Access Consortium, and the top device makers with Singapore plants.</description>
</item>
<item>
  <title>Turkey Pharmaceutical Market 2026: Size, TITCK &amp; Top Companies</title>
  <link>https://www.bionixus.com/blog/turkey-pharmaceutical-market-2026-titck-top-companies</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/turkey-pharmaceutical-market-2026-titck-top-companies</guid>
  <pubDate>Wed, 22 Jul 2026 09:00:00 GMT</pubDate>
  <description>Turkey&apos;s pharmaceutical market in 2026, size and growth, TITCK drug registration steps, reference pricing, and the leading local and multinational companies.</description>
</item>
<item>
  <title>Top Market Research Companies in Egypt 2026: BioNixus vs Kantar, Ipsos</title>
  <link>https://www.bionixus.com/blog/market-research-companies-egypt</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/market-research-companies-egypt</guid>
  <pubDate>Tue, 21 Jul 2026 10:00:00 GMT</pubDate>
  <description>BioNixus wrote this list of market research companies in Egypt for 2026 custom primary research. Compare Kantar, Ipsos, NielsenIQ, IQVIA, and YouGov in Cairo.</description>
</item>
<item>
  <title>HTA Dossier Services in Saudi Arabia: Building SFDA- and NUPCO-Ready Submissions</title>
  <link>https://www.bionixus.com/blog/hta-dossier-saudi-arabia-market-access</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/hta-dossier-saudi-arabia-market-access</guid>
  <pubDate>Mon, 13 Jul 2026 18:43:02 GMT</pubDate>
  <description>Submission-ready HTA dossiers for Saudi Arabia, epidemiology, economic evaluation &amp; budget impact for SFDA and NUPCO pathways.</description>
</item>
<item>
  <title>Online Market Research and Social Listening for Brand Growth (2026 Guide)</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/online-market-research-social-listening-brand-growth-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/online-market-research-social-listening-brand-growth-2026</guid>
  <pubDate>Sun, 28 Jun 2026 22:39:34 GMT</pubDate>
  <description>Guide to online market research and social listening for brand growth and reputation in 2026, MENA methodology, integration, and decision-ready insights.</description>
</item>
<item>
  <title>Financial Services Market Research in Egypt (2026 Guide)</title>
  <link>https://www.bionixus.com/bionixus-industries/insights/financial-services-market-research-egypt-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/bionixus-industries/insights/financial-services-market-research-egypt-2026</guid>
  <pubDate>Sat, 27 Jun 2026 17:13:39 GMT</pubDate>
  <description>2026 guide to financial services market research in Egypt: CBE inclusion data, research methods, and profiles of Ipsos, Kantar, NielsenIQ, Euromonitor.</description>
</item>
<item>
  <title>AI in Drug Discovery: How Machine Learning is Revolutionizing Pharmaceutical R&amp;D in 2026</title>
  <link>https://www.bionixus.com/blog/ai-drug-discovery-machine-learning-pharma-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/ai-drug-discovery-machine-learning-pharma-2026</guid>
  <pubDate>Tue, 23 Jun 2026 09:00:00 GMT</pubDate>
  <description>AI and machine learning in drug discovery 2026, FDA momentum, R&amp;D use cases, and what pharma teams should validate next.</description>
</item>
<item>
  <title>EMA Orphan Drug Designation 2026: Complete Guide to European Rare Disease Regulatory Pathway</title>
  <link>https://www.bionixus.com/blog/ema-orphan-drug-designation-guide-europe-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/ema-orphan-drug-designation-guide-europe-2026</guid>
  <pubDate>Tue, 23 Jun 2026 09:00:00 GMT</pubDate>
  <description>EMA orphan drug designation 2026: faster decisions, evidence expectations, and market access implications for rare disease pharma.</description>
</item>
<item>
  <title>Mercado Farmacêutico Brasileiro 2026: Guia Completo para Entrada de Multinacionais e Estratégia Regulatória ANVISA</title>
  <link>https://www.bionixus.com/blog/mercado-farmaceutico-brasil-guia-anvisa-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/mercado-farmaceutico-brasil-guia-anvisa-2026</guid>
  <pubDate>Tue, 23 Jun 2026 09:00:00 GMT</pubDate>
  <description>Em abril de 2026, a ANVISA simplificou drasticamente o processo de registro de medicamentos biológicos no Brasil, reduzindo prazos em 35%. Este guia.</description>
</item>
<item>
  <title>UAE Pharmaceutical Market 2026: Complete Guide to GCC Market Entry and Regulatory Strategy</title>
  <link>https://www.bionixus.com/blog/uae-pharmaceutical-market-gcc-entry-guide-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/uae-pharmaceutical-market-gcc-entry-guide-2026</guid>
  <pubDate>Tue, 23 Jun 2026 09:00:00 GMT</pubDate>
  <description>In March 2026, the UAE launched a unified GCC drug registration platform enabling access to six Middle Eastern markets with a single.</description>
</item>
<item>
  <title>سوق الأدوية السعودية 2026: دليل شامل للدخول إلى السوق والاستراتيجية التنظيمية في إطار رؤية 2030</title>
  <link>https://www.bionixus.com/blog/souk-adwiya-saudiya-dalil-shamel-rueya-2030-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/souk-adwiya-saudiya-dalil-shamel-rueya-2030-2026</guid>
  <pubDate>Tue, 23 Jun 2026 09:00:00 GMT</pubDate>
  <description>في مايو 2026، أصدرت الهيئة العامة للغذاء والدواء السعودية إرشادات محدثة تقلل أوقات تسجيل الأدوية الحيوية بنسبة 40%, من 14-18 شهراً إلى 8-10 أشهر فقط. هذا.</description>
</item>
<item>
  <title>أبحاث السوق الصيدلانية في السعودية 2026: دليل شامل لدخول السوق الصيدلاني السعودي</title>
  <link>https://www.bionixus.com/blog/saudi-arabia-pharmaceutical-market-research-2026-ar</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-arabia-pharmaceutical-market-research-2026-ar</guid>
  <pubDate>Mon, 22 Jun 2026 09:00:00 GMT</pubDate>
  <description>الهيئة العامة للغذاء والدواء أطلقت مسار الموافقة السريع في 2025 (7 أشهر للأدوية ذات الأولوية) بينما رؤية 2030 تستثمر 64 مليار دولار في تحويل القطاع الصحي.</description>
</item>
<item>
  <title>Pesquisa de Mercado Farmacêutico no Brasil 2026: Guia Completo para Acesso ao Mercado Farmacêutico Brasileiro</title>
  <link>https://www.bionixus.com/blog/pesquisa-mercado-farmaceutico-brasil-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pesquisa-mercado-farmaceutico-brasil-2026</guid>
  <pubDate>Mon, 22 Jun 2026 08:45:00 GMT</pubDate>
  <description>ANVISA implementou eSub 2.0 em 2026, reduzindo aprovações em 35%, enquanto CONITEC adotou diretrizes mais rigorosas. Este guia completo fornece.</description>
</item>
<item>
  <title>Saudi Arabia &amp; GCC Pharmaceutical Market Guide 2026: Complete Entry Strategy for Life Sciences Companies</title>
  <link>https://www.bionixus.com/blog/saudi-arabia-gcc-pharmaceutical-market-guide-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-arabia-gcc-pharmaceutical-market-guide-2026</guid>
  <pubDate>Mon, 22 Jun 2026 08:30:00 GMT</pubDate>
  <description>Saudi Arabia&apos;s SFDA fast-track cuts approval to 7 months while UAE harmonizes 85% of requirements with GCC-DR. This comprehensive guide provides.</description>
</item>
<item>
  <title>European HTA Regulation 2026: Complete Pharmaceutical Market Access Guide for Joint Clinical Assessment</title>
  <link>https://www.bionixus.com/blog/european-hta-regulation-2026-pharmaceutical-market-access-guide</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/european-hta-regulation-2026-pharmaceutical-market-access-guide</guid>
  <pubDate>Mon, 22 Jun 2026 08:15:00 GMT</pubDate>
  <description>EU HTA Regulation 2026: joint clinical assessment timelines, evidence needs &amp; market access steps for pharma. BioNixus practical guide.</description>
</item>
<item>
  <title>Real World Evidence for FDA Submissions: Complete 2026 Guide for Pharmaceutical Companies</title>
  <link>https://www.bionixus.com/blog/real-world-evidence-fda-guide-pharmaceutical-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/real-world-evidence-fda-guide-pharmaceutical-2026</guid>
  <pubDate>Mon, 22 Jun 2026 08:00:00 GMT</pubDate>
  <description>FDA real-world evidence for pharma 2026: Cures Act framework, guidance landscape &amp; how RWE supports access and medical decisions.</description>
</item>
<item>
  <title>AMNOG und frühe Nutzenbewertung 2026: Leitfaden für Market-Access-Teams</title>
  <link>https://www.bionixus.com/blog/amnog-frueher-nutzen-marktzugang-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/amnog-frueher-nutzen-marktzugang-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Leitfaden zum AMNOG-Verfahren: G-BA, IQWiG, Zusatznutzen, Preisverhandlungen GKV-Spitzenverband, Orphan Drugs und Marktforschung für die.</description>
</item>
<item>
  <title>Avaliação de tecnologias CONITEC: acesso ao SUS no Brasil (2026)</title>
  <link>https://www.bionixus.com/blog/avaliacao-tecnologias-conitec-brasil-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/avaliacao-tecnologias-conitec-brasil-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Avaliação de tecnologias CONITEC no Brasil 2026: ANVISA, SUS, prazos HTA e mercado privado vs público. BioNixus pharmaceutical and healthcare market</description>
</item>
<item>
  <title>Évaluation économique HAS : CEESP et accès au marché en France (2026)</title>
  <link>https://www.bionixus.com/blog/evaluation-economique-has-france-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/evaluation-economique-has-france-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Évaluation économique HAS et CEESP en France 2026 : déclencheurs ASMR, LFSS fast-track, avis médico-économiques et accès au marché.</description>
</item>
<item>
  <title>Farmacoeconomía y acceso al mercado en España: RD 415/2026</title>
  <link>https://www.bionixus.com/blog/farmacoeconomia-acceso-mercado-espana-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/farmacoeconomia-acceso-mercado-espana-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Farmacoeconomía y acceso al mercado en España 2026: RD 415/2026, AEMPS, evaluación HTA y financiación autonómica. BioNixus pharmaceutical and healthcare</description>
</item>
<item>
  <title>Market Access Research in the UAE: A 2026 Guide for Pharma Launch Teams</title>
  <link>https://www.bionixus.com/blog/market-access-research-uae-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/market-access-research-uae-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Market access research in the UAE for 2026: EDE pricing, DoH UPP reimbursement, DHA formularies, and primary research for pharma launch teams in Dubai and.</description>
</item>
<item>
  <title>NMPA与NRDL医药市场研究：2026年注册与准入证据规划</title>
  <link>https://www.bionixus.com/blog/nmpa-pharmaceutical-market-research-china-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/nmpa-pharmaceutical-market-research-china-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>NMPA与NRDL医药市场研究2026：注册证据、CDE受理、医保谈判与本地MR方法。 BioNixus pharmaceutical and healthcare market research.</description>
</item>
<item>
  <title>Oncology Market Research in the USA: Payer and Clinical Insights for 2026</title>
  <link>https://www.bionixus.com/blog/oncology-market-research-usa-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/oncology-market-research-usa-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Oncology market research in the USA for 2026: CMS EOM, NCCN pathways, payer prior auth, KOL insights, and launch research for pharmaceutical teams.</description>
</item>
<item>
  <title>Pharmacoeconomics Consulting in Europe: HEOR Evidence for Payer Negotiations (2026)</title>
  <link>https://www.bionixus.com/blog/pharmacoeconomics-consulting-europe-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmacoeconomics-consulting-europe-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Pharmacoeconomics consulting in Europe for 2026: CEA, budget impact, G-BA AMNOG, HAS CEESP, and Spain RD 415/2026, HEOR evidence for payer negotiations.</description>
</item>
<item>
  <title>Доступ на рынок ЕАЭС: регистрация и локализация в 2026</title>
  <link>https://www.bionixus.com/blog/eaeu-farmacevticheskiy-dostup-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/eaeu-farmacevticheskiy-dostup-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>Фармацевтический доступ ЕАЭС 2026: регистрация, локализация ПП 719, GRLS/VED и исследование рынка. BioNixus pharmaceutical and healthcare market research.</description>
</item>
<item>
  <title>استشارات HEOR في السعودية: دليل أبحاث الصحة الاقتصادية 2026</title>
  <link>https://www.bionixus.com/blog/heor-consulting-saudi-arabia-ar-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/heor-consulting-saudi-arabia-ar-2026</guid>
  <pubDate>Fri, 19 Jun 2026 08:00:00 GMT</pubDate>
  <description>دليل استشارات HEOR في السعودية 2026: SFDA EES، NUPCO، CHI، نماذج أثر ميزاني، وأبحاث pharmacoeconomics لفرق الأدوية. BioNixus pharmaceutical and healthcare</description>
</item>
<item>
  <title>2026年医药市场研究指南：全球药企亚太证据策略</title>
  <link>https://www.bionixus.com/blog/pharmaceutical-market-research-china-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmaceutical-market-research-china-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>2026年医药市场研究指南：全球药企亚太证据策略、NMPA、医保谈判与 primary research 方法。 BioNixus pharmaceutical and healthcare market research.</description>
</item>
<item>
  <title>EMA HTA Evidence Requirements for Pharmaceutical Market Access in Europe (2026)</title>
  <link>https://www.bionixus.com/blog/ema-hta-evidence-requirements-europe-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/ema-hta-evidence-requirements-europe-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>How EU HTA Regulation, joint clinical assessment, and real-world evidence shape pharmaceutical market access in Europe, with country-level pricing.</description>
</item>
<item>
  <title>Études de marché pharmaceutique en France 2026 : HAS, accès et recherche</title>
  <link>https://www.bionixus.com/blog/etudes-marche-pharmaceutique-france-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/etudes-marche-pharmaceutique-france-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>Études de marché pharmaceutique en France 2026 : HAS, accès au marché, CEESP et recherche primaire pour dossiers crédibles.</description>
</item>
<item>
  <title>FDA Real-World Evidence for Market Access: A 2026 Guide for Pharma Teams</title>
  <link>https://www.bionixus.com/blog/fda-real-world-evidence-market-access-usa-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/fda-real-world-evidence-market-access-usa-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>FDA real-world evidence framework, payer vs FDA evidence needs, and RWE design for US pharmaceutical market access, a 2026 guide for pharma and HEOR.</description>
</item>
<item>
  <title>Investigación de mercado farmacéutico en España 2026: guía para equipos de acceso</title>
  <link>https://www.bionixus.com/blog/investigacion-mercado-farmaceutico-espana-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/investigacion-mercado-farmaceutico-espana-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>Investigación de mercado farmacéutico en España 2026: AEMPS, acceso autonómico, RWE y estudios primarios para equipos de market access.</description>
</item>
<item>
  <title>Pesquisa de mercado farmacêutico no Brasil 2026: ANVISA, CONITEC e lançamento</title>
  <link>https://www.bionixus.com/blog/pesquisa-mercado-farmaceutico-brasil-anvisa-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pesquisa-mercado-farmaceutico-brasil-anvisa-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>Pesquisa de mercado farmacêutico no Brasil 2026: ANVISA, CONITEC, incorporação SUS e estudos primários para lançamento. BioNixus pharmaceutical and</description>
</item>
<item>
  <title>Pharmamarktforschung in Deutschland 2026: Methoden, KVen, RWE und KOL-Netzwerke</title>
  <link>https://www.bionixus.com/blog/pharmamarktforschung-deutschland-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmamarktforschung-deutschland-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>Leitfaden zur Pharmamarktforschung in Deutschland: GKV/PKV-Struktur, Kassenärztliche Vereinigungen, Ärztebefragungen, KOL-Mapping, RWE-Daten und.</description>
</item>
<item>
  <title>Фармацевтические исследования рынка 2026: методология и доступ на рынок</title>
  <link>https://www.bionixus.com/blog/farmacevticheskie-issledovaniya-rynka-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/farmacevticheskie-issledovaniya-rynka-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>Фармацевтические исследования рынка 2026: методология, доступ на рынок, RWE и primary research для pharma-команд. BioNixus pharmaceutical and healthcare</description>
</item>
<item>
  <title>دليل أبحاث السوق الصحي في المملكة العربية السعودية 2026</title>
  <link>https://www.bionixus.com/blog/saudi-healthcare-market-research-guide-ar-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-healthcare-market-research-guide-ar-2026</guid>
  <pubDate>Thu, 18 Jun 2026 12:00:00 GMT</pubDate>
  <description>دليل 2026 لأبحاث السوق الصحي والدوائي في المملكة: SFDA وNUPCO، المنهجيات الكمية والنوعية، والمجالات العلاجية ذات الأولوية.</description>
</item>
<item>
  <title>SFDA Economic Evaluation Studies: Building a Budget Impact Model for Saudi Arabia (2026)</title>
  <link>https://www.bionixus.com/blog/sfda-economic-evaluation-budget-impact-guide-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/sfda-economic-evaluation-budget-impact-guide-2026</guid>
  <pubDate>Thu, 18 Jun 2026 08:00:00 GMT</pubDate>
  <description>How to build a Saudi budget impact model for SFDA economic evaluation: payer perspective, 3, 5 year horizon, local epidemiology, and NUPCO-ready scenarios.</description>
</item>
<item>
  <title>What Skyrizi&apos;s July TV Spend Means for Omnichannel Engagement</title>
  <link>https://www.bionixus.com/blog/skyrizi-tops-julys-pharma-rankings-and-what-it-means-for-omnichannel-engagement</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/skyrizi-tops-julys-pharma-rankings-and-what-it-means-for-omnichannel-engagement</guid>
  <pubDate>Fri, 12 Jun 2026 10:00:00 GMT</pubDate>
  <description>Skyrizi July TV ad spend and impression share, and what that means for omnichannel engagement, HCP digital and promotional ROI.</description>
</item>
<item>
  <title>In Vitro Diagnostics (IVD) Market in Saudi Arabia 2026: SFDA Regulation, Molecular Diagnostics, and Hospital Procurement Intelligence</title>
  <link>https://www.bionixus.com/blog/saudi-arabia-in-vitro-diagnostics-market</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-arabia-in-vitro-diagnostics-market</guid>
  <pubDate>Sun, 07 Jun 2026 14:44:12 GMT</pubDate>
  <description>Saudi Arabia in vitro diagnostics market ~USD 0.9, 1.1B in 2026 (BioNixus analysis): SFDA MDMA registration, molecular diagnostics growth, NUPCO and lab.</description>
</item>
<item>
  <title>Lilly obesity portfolio: Commercial and PBM, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/obesity-pbm-coverage-lilly-portfolio-q2-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/obesity-pbm-coverage-lilly-portfolio-q2-2026</guid>
  <pubDate>Thu, 28 May 2026 00:00:00 GMT</pubDate>
  <description>Lilly obesity portfolio (orforglipron / tirzepatide): Gulf market access after Commercial and PBM, SFDA registration, MOHAP pa...</description>
</item>
<item>
  <title>Camizestrant: FDA PDUFA extension, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/camizestrant-pdufa-extension-astrazeneca-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/camizestrant-pdufa-extension-astrazeneca-2026</guid>
  <pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate>
  <description>Camizestrant (camizestrant): Gulf market access after FDA PDUFA extension, SFDA registration, MOHAP pathways, and NUPCO tender...</description>
</item>
<item>
  <title>Decnupaz: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/decnupaz-pivekimab-bpdcn-fda-approval-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/decnupaz-pivekimab-bpdcn-fda-approval-2026</guid>
  <pubDate>Wed, 27 May 2026 00:00:00 GMT</pubDate>
  <description>Decnupaz (pivekimab sunirine): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender impl...</description>
</item>
<item>
  <title>Desmoid Market Access Briefing: Ogsiveo (nirogacestat), FDA Approval &amp; Access Signals</title>
  <link>https://www.bionixus.com/blog/desmoid-tumors-nirogacestat-pharma-market-access</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/desmoid-tumors-nirogacestat-pharma-market-access</guid>
  <pubDate>Tue, 26 May 2026 11:30:00 GMT</pubDate>
  <description>Desmoid tumours and Ogsiveo (nirogacestat): FDA approval, access signals, tumour-board adoption, and Gulf tender analogues for pharma research teams.</description>
</item>
<item>
  <title>Koselugo (Selumetinib) Market Research: NF1 Plexiform Neurofibroma Access &amp; Launch Signals</title>
  <link>https://www.bionixus.com/blog/nf1-koselugo-selumetinib-pharma-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/nf1-koselugo-selumetinib-pharma-market-research</guid>
  <pubDate>Tue, 26 May 2026 09:00:00 GMT</pubDate>
  <description>Koselugo (selumetinib) market research for NF1 plexiform neurofibromas, FDA chronology, EU vs EZMEKLY, launch economics, and specialist adoption.</description>
</item>
<item>
  <title>NF1 Market Access Briefing: Neurofibromatosis, MEK Inhibition &amp; HCP Evidence Signals</title>
  <link>https://www.bionixus.com/blog/neurofibromatosis</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/neurofibromatosis</guid>
  <pubDate>Tue, 26 May 2026 09:00:00 GMT</pubDate>
  <description>NF1 and MEK inhibition for plexiform neurofibromas, FDA paediatric approvals, EU EZMEKLY context, and how pharma teams localize payer evidence.</description>
</item>
<item>
  <title>Lilly vaccine platform: M&amp;A, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/eli-lilly-vaccine-acquisitions-curevo-limmatech-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/eli-lilly-vaccine-acquisitions-curevo-limmatech-2026</guid>
  <pubDate>Tue, 26 May 2026 00:00:00 GMT</pubDate>
  <description>Lilly vaccine platform (multi-asset vaccine portfolio): Gulf market access after M&amp;A, SFDA registration, MOHAP pathways, and N...</description>
</item>
<item>
  <title>Datroway: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/datroway-datopotamab-tnbc-fda-approval-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/datroway-datopotamab-tnbc-fda-approval-2026</guid>
  <pubDate>Fri, 22 May 2026 00:00:00 GMT</pubDate>
  <description>Datroway (datopotamab deruxtecan): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender...</description>
</item>
<item>
  <title>Hepcludex: FDA Accelerated Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/hepcludex-bulevirtide-hdv-fda-approval-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/hepcludex-bulevirtide-hdv-fda-approval-2026</guid>
  <pubDate>Fri, 22 May 2026 00:00:00 GMT</pubDate>
  <description>Hepcludex (bulevirtide): Gulf market access after FDA Accelerated Approval, SFDA registration, MOHAP pathways, and NUPCO tende...</description>
</item>
<item>
  <title>Jascayd: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/jascayd-nerandomilast-ema-chmp-ipf-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/jascayd-nerandomilast-ema-chmp-ipf-2026</guid>
  <pubDate>Thu, 21 May 2026 00:00:00 GMT</pubDate>
  <description>Jascayd (nerandomilast): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways, and NUPCO tend...</description>
</item>
<item>
  <title>Vijoice: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/vijoice-alpelisib-pros-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/vijoice-alpelisib-pros-ema-chmp-2026</guid>
  <pubDate>Thu, 21 May 2026 00:00:00 GMT</pubDate>
  <description>Vijoice (alpelisib): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways, and NUPCO tender i...</description>
</item>
<item>
  <title>GCC Clinical Trials Market 2026: Regulatory Landscape, Key Sites, and Research Opportunities</title>
  <link>https://www.bionixus.com/blog/gcc-clinical-trials-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/gcc-clinical-trials-market-2026</guid>
  <pubDate>Tue, 19 May 2026 21:30:00 GMT</pubDate>
  <description>GCC clinical trials market 2026: regulatory landscape by country, key sites, therapy activity &amp; recruitment for sponsors.</description>
</item>
<item>
  <title>How Pharmaceutical Market Research Works in MENA: Methods and Data Sources</title>
  <link>https://www.bionixus.com/blog/pharmaceutical-market-research-methods-mena</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmaceutical-market-research-methods-mena</guid>
  <pubDate>Tue, 19 May 2026 21:00:00 GMT</pubDate>
  <description>How pharmaceutical market research works in MENA, physician surveys, hospital data, KOL mapping &amp; market access methods.</description>
</item>
<item>
  <title>Saudi Arabia Healthcare Market 2026: Hospital Data, NUPCO, SFDA, and Vision 2030</title>
  <link>https://www.bionixus.com/blog/saudi-arabia-healthcare-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/saudi-arabia-healthcare-market-2026</guid>
  <pubDate>Tue, 19 May 2026 20:00:00 GMT</pubDate>
  <description>Saudi healthcare market 2026: hospital data, NUPCO, SFDA &amp; Vision 2030 for pharma and medtech teams. BioNixus market research overview.</description>
</item>
<item>
  <title>GCC Pharmacy Market 2026: Size, Sales Data, and Pharmaceutical Trends</title>
  <link>https://www.bionixus.com/blog/gcc-pharmacy-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/gcc-pharmacy-market-2026</guid>
  <pubDate>Tue, 19 May 2026 19:00:00 GMT</pubDate>
  <description>Comprehensive analysis of the GCC pharmacy market in 2026, total market size, pharmaceutical sales by country, retail and hospital pharmacy dynamics, gene</description>
</item>
<item>
  <title>UAE Healthcare Market 2026: Hospital Data, Pharmaceutical Sales, and Market Access</title>
  <link>https://www.bionixus.com/blog/uae-healthcare-market-overview-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/uae-healthcare-market-overview-2026</guid>
  <pubDate>Tue, 19 May 2026 18:00:00 GMT</pubDate>
  <description>UAE healthcare market 2026: hospital &amp; pharma sales, DHA/MOHAP access &amp; private vs public uptake. BioNixus research for launch teams.</description>
</item>
<item>
  <title>Baxfendy: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/baxfendy-baxdrostat-hypertension-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/baxfendy-baxdrostat-hypertension-fda-2026</guid>
  <pubDate>Fri, 15 May 2026 00:00:00 GMT</pubDate>
  <description>Baxfendy (baxdrostat): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender implications...</description>
</item>
<item>
  <title>Market Research &amp; Marketing Automation for Pharmacies in Saudi Arabia: How to Grow Retail Sales and Customer Satisfaction</title>
  <link>https://www.bionixus.com/blog/pharmacies-saudi-arabia-market-research-marketing-automation</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmacies-saudi-arabia-market-research-marketing-automation</guid>
  <pubDate>Wed, 13 May 2026 16:11:04 GMT</pubDate>
  <description>A comprehensive guide to leveraging market research and marketing automation to grow pharmacy retail sales in Saudi Arabia. Covers key players (Nahdi, Al-D</description>
</item>
<item>
  <title>Beqalzi: FDA Accelerated Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/beqalzi-sonrotoclax-mcl-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/beqalzi-sonrotoclax-mcl-fda-2026</guid>
  <pubDate>Wed, 13 May 2026 00:00:00 GMT</pubDate>
  <description>Beqalzi (sonrotoclax): Gulf market access after FDA Accelerated Approval, SFDA registration, MOHAP pathways, and NUPCO tender...</description>
</item>
<item>
  <title>Langlara: FDA Approval (Interchangeable), Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/langlara-insulin-glargine-biosimilar-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/langlara-insulin-glargine-biosimilar-fda-2026</guid>
  <pubDate>Wed, 29 Apr 2026 00:00:00 GMT</pubDate>
  <description>Langlara (insulin glargine-aldy): Gulf market access after FDA Approval (Interchangeable), SFDA registration, MOHAP pathways,...</description>
</item>
<item>
  <title>Cenrifki: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/cenrifki-tolebrutinib-nrspms-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/cenrifki-tolebrutinib-nrspms-ema-chmp-2026</guid>
  <pubDate>Thu, 23 Apr 2026 00:00:00 GMT</pubDate>
  <description>Cenrifki (tolebrutinib): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways, and NUPCO tend...</description>
</item>
<item>
  <title>Itvisma: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/itvisma-onasemnogene-sma-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/itvisma-onasemnogene-sma-ema-chmp-2026</guid>
  <pubDate>Thu, 23 Apr 2026 00:00:00 GMT</pubDate>
  <description>Itvisma (onasemnogene abeparvovec): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways, and...</description>
</item>
<item>
  <title>Redemplo: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/redemplo-plozasiran-fcs-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/redemplo-plozasiran-fcs-ema-chmp-2026</guid>
  <pubDate>Thu, 23 Apr 2026 00:00:00 GMT</pubDate>
  <description>Redemplo (plozasiran): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways, and NUPCO tender...</description>
</item>
<item>
  <title>Idvynso: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/idvynso-doravirine-islatravir-hiv-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/idvynso-doravirine-islatravir-hiv-fda-2026</guid>
  <pubDate>Tue, 21 Apr 2026 00:00:00 GMT</pubDate>
  <description>Idvynso (doravirine + islatravir): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender...</description>
</item>
<item>
  <title>Tecartus: FDA Full Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/tecartus-brexucabtagene-mcl-full-approval-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/tecartus-brexucabtagene-mcl-full-approval-2026</guid>
  <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
  <description>Tecartus (brexucabtagene autoleucel): Gulf market access after FDA Full Approval, SFDA registration, MOHAP pathways, and NUPCO...</description>
</item>
<item>
  <title>Digital Therapeutics Regulation in MENA Markets: SFDA, UAE, and North Africa Pathways for Pharma and MedTech</title>
  <link>https://www.bionixus.com/blog/digital-therapeutics-regulation-mena-markets</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/digital-therapeutics-regulation-mena-markets</guid>
  <pubDate>Sat, 18 Apr 2026 17:13:15 GMT</pubDate>
  <description>A consultant-style guide to digital therapeutics regulation in MENA: GCC SaMD pathways, SFDA and UAE authority structures, North African developments, clin</description>
</item>
<item>
  <title>Vasa CAMKII platform: R&amp;D Partnership, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/vasa-lilly-tunelab-camkii-cardiovascular-ai-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/vasa-lilly-tunelab-camkii-cardiovascular-ai-2026</guid>
  <pubDate>Wed, 15 Apr 2026 00:00:00 GMT</pubDate>
  <description>Vasa CAMKII platform (AI/ML cardiovascular candidates): Gulf market access after R&amp;D Partnership, SFDA registration, MOHAP pat...</description>
</item>
<item>
  <title>PathAI platform: M&amp;A, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/roche-pathai-acquisition-digital-pathology-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/roche-pathai-acquisition-digital-pathology-2026</guid>
  <pubDate>Mon, 06 Apr 2026 00:00:00 GMT</pubDate>
  <description>PathAI platform (digital pathology AI): Gulf market access after M&amp;A, SFDA registration, MOHAP pathways, and NUPCO tender impl...</description>
</item>
<item>
  <title>Zepbound KwikPen: Commercial Access, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/zepbound-kwikpen-goodrx-self-pay-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/zepbound-kwikpen-goodrx-self-pay-2026</guid>
  <pubDate>Thu, 02 Apr 2026 00:00:00 GMT</pubDate>
  <description>Zepbound KwikPen (tirzepatide): Gulf market access after Commercial Access, SFDA registration, MOHAP pathways, and NUPCO tende...</description>
</item>
<item>
  <title>Foundayo: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/foundayo-orforglipron-fda-approval-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/foundayo-orforglipron-fda-approval-2026</guid>
  <pubDate>Wed, 01 Apr 2026 00:00:00 GMT</pubDate>
  <description>Foundayo (orforglipron): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender implicatio...</description>
</item>
<item>
  <title>Kresladi: FDA Accelerated Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/kresladi-marnetegragene-lad1-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/kresladi-marnetegragene-lad1-fda-2026</guid>
  <pubDate>Fri, 27 Mar 2026 00:00:00 GMT</pubDate>
  <description>Kresladi (marnetegragene autotemcel): Gulf market access after FDA Accelerated Approval, SFDA registration, MOHAP pathways, an...</description>
</item>
<item>
  <title>Adstiladrin: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/adstiladrin-nadofaragene-nmibc-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/adstiladrin-nadofaragene-nmibc-ema-chmp-2026</guid>
  <pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate>
  <description>Adstiladrin (nadofaragene firadenovec): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways,...</description>
</item>
<item>
  <title>Awiqli: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/awiqli-insulin-icodec-weekly-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/awiqli-insulin-icodec-weekly-fda-2026</guid>
  <pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate>
  <description>Awiqli (insulin icodec): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender implicatio...</description>
</item>
<item>
  <title>Imdylltra: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/imdylltra-tarlatamab-sclc-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/imdylltra-tarlatamab-sclc-ema-chmp-2026</guid>
  <pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate>
  <description>Imdylltra (tarlatamab): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways, and NUPCO tende...</description>
</item>
<item>
  <title>Joenja: EMA CHMP (Exceptional Circumstances), Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/joenja-leniolisib-apds-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/joenja-leniolisib-apds-ema-chmp-2026</guid>
  <pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate>
  <description>Joenja (leniolisib): Gulf market access after EMA CHMP (Exceptional Circumstances), SFDA registration, MOHAP pathways, and NUP...</description>
</item>
<item>
  <title>Zepzelca: EMA CHMP Positive Opinion, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/zepzelca-lurbinectedin-sclc-ema-chmp-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/zepzelca-lurbinectedin-sclc-ema-chmp-2026</guid>
  <pubDate>Thu, 26 Mar 2026 00:00:00 GMT</pubDate>
  <description>Zepzelca (lurbinectedin): Gulf market access after EMA CHMP Positive Opinion, SFDA registration, MOHAP pathways, and NUPCO ten...</description>
</item>
<item>
  <title>Lifyorli: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/lifyorli-relacorilant-ovarian-cancer-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/lifyorli-relacorilant-ovarian-cancer-fda-2026</guid>
  <pubDate>Wed, 25 Mar 2026 00:00:00 GMT</pubDate>
  <description>Lifyorli (relacorilant): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender implicatio...</description>
</item>
<item>
  <title>Lynavoy: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/lynarvo-linerixibat-pbc-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/lynarvo-linerixibat-pbc-fda-2026</guid>
  <pubDate>Thu, 19 Mar 2026 00:00:00 GMT</pubDate>
  <description>Lynavoy (linerixibat): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender implications...</description>
</item>
<item>
  <title>Icotyde: FDA Approval, Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/icotyde-icotrokinra-psoriasis-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/icotyde-icotrokinra-psoriasis-fda-2026</guid>
  <pubDate>Wed, 18 Mar 2026 00:00:00 GMT</pubDate>
  <description>Icotyde (icotrokinra): Gulf market access after FDA Approval, SFDA registration, MOHAP pathways, and NUPCO tender implications...</description>
</item>
<item>
  <title>Quantitative Healthcare Market Research in UAE: Methodology and Execution Guide</title>
  <link>https://www.bionixus.com/blog/quantitative-healthcare-market-research-uae</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/quantitative-healthcare-market-research-uae</guid>
  <pubDate>Sat, 14 Mar 2026 08:30:00 GMT</pubDate>
  <description>Quantitative healthcare market research in UAE helps pharmaceutical teams convert physician and stakeholder feedback into measurable strategy. This guide.</description>
</item>
<item>
  <title>Quantitative Healthcare Market Research in KSA: Practical Guide for Pharmaceutical Teams</title>
  <link>https://www.bionixus.com/blog/quantitative-healthcare-market-research-ksa</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/quantitative-healthcare-market-research-ksa</guid>
  <pubDate>Sat, 14 Mar 2026 08:00:00 GMT</pubDate>
  <description>Quantitative healthcare market research in KSA requires robust survey design, verified HCP sampling, and defensible QA controls. This guide shows how pharm</description>
</item>
<item>
  <title>GCC Pharmaceuticals Market 2026: Size, Growth Drivers, and Access Strategy</title>
  <link>https://www.bionixus.com/blog/gcc-pharmaceuticals-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/gcc-pharmaceuticals-market-2026</guid>
  <pubDate>Thu, 05 Mar 2026 23:49:26 GMT</pubDate>
  <description>GCC pharmaceuticals market 2026: size, growth drivers, specialty therapies &amp; access strategy across KSA, UAE &amp; Kuwait. BioNixus research.</description>
</item>
<item>
  <title>Quantitative Market Research and Market Access Impact</title>
  <link>https://www.bionixus.com/blog/quantitative-market-research-and-market-access</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/quantitative-market-research-and-market-access</guid>
  <pubDate>Thu, 05 Mar 2026 23:47:06 GMT</pubDate>
  <description>Quantitative healthcare market research for pharma market access, KPIs, payer evidence, MENA/GCC design &amp; pricing scenarios. Read the guide.</description>
</item>
<item>
  <title>Flovent HFA generic: FDA Approval (Interchangeable), Gulf SFDA, MOHAP &amp; NUPCO Access</title>
  <link>https://www.bionixus.com/blog/flovent-hfa-fluticasone-generic-fda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/flovent-hfa-fluticasone-generic-fda-2026</guid>
  <pubDate>Tue, 03 Mar 2026 00:00:00 GMT</pubDate>
  <description>Flovent HFA generic (fluticasone propionate MDI): Gulf market access after FDA Approval (Interchangeable), SFDA registration,...</description>
</item>
<item>
  <title>Abu Dhabi DOH vs. Dubai DHA: The 2026 Formulary Submission Guide for the UAE</title>
  <link>https://www.bionixus.com/blog/abu-dhabi-doh-vs-dubai-dha-formulary-guide</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/abu-dhabi-doh-vs-dubai-dha-formulary-guide</guid>
  <pubDate>Mon, 02 Mar 2026 08:00:00 GMT</pubDate>
  <description>2026 formulary submission guide: how Abu Dhabi DOH and Dubai DHA pathways differ for UAE pharmaceutical market access. BioNixus pharmaceutical and</description>
</item>
<item>
  <title>GCC Pharmacoeconomics: Health Economics, HTA Signals &amp; Tender Evidence</title>
  <link>https://www.bionixus.com/blog/gcc-pharmacoeconomics</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/gcc-pharmacoeconomics</guid>
  <pubDate>Sun, 01 Mar 2026 10:00:00 GMT</pubDate>
  <description>GCC pharmacoeconomics playbook: Saudi &amp; UAE payer cues, tender dossiers, BIA vs CEA sequencing, comparator localization, BioNixus HEOR.</description>
</item>
<item>
  <title>NUPCO Saudi Arabia: The 2026 Pharmaceutical Tendering and Procurement Guide</title>
  <link>https://www.bionixus.com/blog/nupco-saudi-arabia-tendering-guide</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/nupco-saudi-arabia-tendering-guide</guid>
  <pubDate>Sun, 01 Mar 2026 08:00:00 GMT</pubDate>
  <description>NUPCO pharmaceutical tendering and procurement in Saudi Arabia 2026, what sponsors need for institutional market access.</description>
</item>
<item>
  <title>Geopolitical Contagion: Assessing the Impact of a Regional Crisis on Middle East Economies and Healthcare Resilience (2026 Strategy)</title>
  <link>https://www.bionixus.com/blog/regional-crisis-impact-middle-east-economies-healthcare-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/regional-crisis-impact-middle-east-economies-healthcare-2026</guid>
  <pubDate>Sat, 28 Feb 2026 14:30:00 GMT</pubDate>
  <description>A deep-dive analysis into how a major regional conflict in 2026 would disrupt currency stability, oil dependencies, and the healthcare supply chain across.</description>
</item>
<item>
  <title>Middle East Healthcare Market Statistics 2026: Comprehensive Data &amp; Growth Metrics</title>
  <link>https://www.bionixus.com/blog/middle-east-healthcare-market-statistics-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/middle-east-healthcare-market-statistics-2026</guid>
  <pubDate>Sat, 28 Feb 2026 10:09:00 GMT</pubDate>
  <description>The ultimate compilation of verified healthcare statistics for the Middle East in 2026. Discover market size, pharmaceutical spending, diabetes prevalence,</description>
</item>
<item>
  <title>Patient Journey Mapping in Saudi Arabia: Methodology and Best Practices</title>
  <link>https://www.bionixus.com/blog/patient-journey-mapping-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/patient-journey-mapping-saudi-arabia</guid>
  <pubDate>Sat, 28 Feb 2026 10:08:00 GMT</pubDate>
  <description>A detailed methodology for mapping the patient journey within the Saudi Arabian healthcare system. Understand cultural nuances, caregiver influence, and.</description>
</item>
<item>
  <title>NICE HTA Evidence Requirements: A Guide for Pharma Entering the UK</title>
  <link>https://www.bionixus.com/blog/nice-hta-evidence-requirements-guide</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/nice-hta-evidence-requirements-guide</guid>
  <pubDate>Sat, 28 Feb 2026 10:07:00 GMT</pubDate>
  <description>A comprehensive guide for pharmaceutical companies navigating the National Institute for Health and Care Excellence (NICE) Health Technology Assessment (HT</description>
</item>
<item>
  <title>Pharma Market Entry in Saudi Arabia: The Complete Playbook</title>
  <link>https://www.bionixus.com/blog/pharma-market-entry-saudi-arabia-playbook</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharma-market-entry-saudi-arabia-playbook</guid>
  <pubDate>Sat, 28 Feb 2026 10:05:00 GMT</pubDate>
  <description>A strategic blueprint for pharmaceutical companies entering Saudi Arabia. Learn about localization requirements (NUPCO), distributor selection, direct inve</description>
</item>
<item>
  <title>Top 10 Therapy Areas Driving Pharma Growth in Saudi Arabia</title>
  <link>https://www.bionixus.com/blog/top-therapy-areas-pharma-growth-saudi-arabia</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/top-therapy-areas-pharma-growth-saudi-arabia</guid>
  <pubDate>Sat, 28 Feb 2026 10:04:00 GMT</pubDate>
  <description>Analyze the fastest-growing therapeutic segments in the Saudi Arabian pharmaceutical market for 2026, driven by Vision 2030 and shifting demographic health</description>
</item>
<item>
  <title>Market Access Strategy for Pharma in the UAE: DOH vs MOHAP Pathways</title>
  <link>https://www.bionixus.com/blog/market-access-strategy-uae</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/market-access-strategy-uae</guid>
  <pubDate>Sat, 28 Feb 2026 10:03:00 GMT</pubDate>
  <description>A complete guide to pharmaceutical market access in the UAE. Understand the distinct regulatory pathways, pricing mechanisms, and formulary access strategi</description>
</item>
<item>
  <title>KOL Mapping for Pharma Companies in the Middle East: Complete Guide</title>
  <link>https://www.bionixus.com/blog/kol-mapping-pharma-middle-east</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/kol-mapping-pharma-middle-east</guid>
  <pubDate>Sat, 28 Feb 2026 10:02:00 GMT</pubDate>
  <description>A comprehensive guide on designing effective Key Opinion Leader (KOL) mapping studies in Saudi Arabia, the UAE, and the wider Middle East for pharmaceutica</description>
</item>
<item>
  <title>Healthcare Market Research Methodologies: CATI vs CAPI vs Online in GCC</title>
  <link>https://www.bionixus.com/blog/healthcare-market-research-methodologies-gcc</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/healthcare-market-research-methodologies-gcc</guid>
  <pubDate>Sat, 28 Feb 2026 10:01:00 GMT</pubDate>
  <description>A deep dive into pharmaceutical research methods in the Middle East. Compare CATI, CAPI, and Online methodologies for engaging healthcare professionals.</description>
</item>
<item>
  <title>Pharmaceutical Product Registration in Saudi Arabia: SFDA Guide 2026</title>
  <link>https://www.bionixus.com/blog/sfda-drug-registration-guide</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/sfda-drug-registration-guide</guid>
  <pubDate>Sat, 28 Feb 2026 10:00:00 GMT</pubDate>
  <description>A comprehensive guide for pharmaceutical companies navigating the SFDA drug registration process in Saudi Arabia, covering pathways, timelines, costs,.</description>
</item>
<item>
  <title>The Shift to &quot;Always-On&quot; Quantitative Tracking: Why Periodic Studies Are Dying</title>
  <link>https://www.bionixus.com/blog/shift-to-always-on-quantitative-tracking-why-periodic-studies-are-dying</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/shift-to-always-on-quantitative-tracking-why-periodic-studies-are-dying</guid>
  <pubDate>Wed, 25 Feb 2026 02:28:00 GMT</pubDate>
  <description>The Shift to &quot;Always-On&quot; Quantitative Tracking: Why Periodic Studies Are Dying: GCC and multinational market access, payer strategy, and healthcare market.</description>
</item>
<item>
  <title>Data Privacy Beyond HIPAA: Navigating Global Quantitative Research Compliance in 2026</title>
  <link>https://www.bionixus.com/blog/data-privacy-beyond-hipaa-global-quantitative-research-compliance-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/data-privacy-beyond-hipaa-global-quantitative-research-compliance-2026</guid>
  <pubDate>Wed, 25 Feb 2026 02:26:00 GMT</pubDate>
  <description>In healthcare quantitative research, compliance is no longer only legal hygiene, it is a trust and competitiveness issue. Buyers increasingly evaluate vendo</description>
</item>
<item>
  <title>Recruiting High-Scarcity Specialists: Best Practices for Oncology Quantitative Studies</title>
  <link>https://www.bionixus.com/blog/recruiting-high-scarcity-specialists-oncology-quantitative-studies</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/recruiting-high-scarcity-specialists-oncology-quantitative-studies</guid>
  <pubDate>Wed, 25 Feb 2026 02:24:00 GMT</pubDate>
  <description>The Recruitment Constraint in Modern Oncology Research Oncology quantitative studies increasingly require niche respondents: tumor-board decisio.</description>
</item>
<item>
  <title>MaxDiff vs. Conjoint Analysis: Which Quantitative Method Wins for MedTech Pricing?</title>
  <link>https://www.bionixus.com/blog/maxdiff-vs-conjoint-analysis-medtech-pricing</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/maxdiff-vs-conjoint-analysis-medtech-pricing</guid>
  <pubDate>Wed, 25 Feb 2026 02:22:00 GMT</pubDate>
  <description>The MedTech Pricing Decision Most Teams Get Wrong When MedTech companies evaluate pricing architecture, many teams ask, “Should we run MaxDiff.</description>
</item>
<item>
  <title>AI vs. Human Insight: Validating Quantitative Data in 2026 Pharma Research</title>
  <link>https://www.bionixus.com/blog/ai-vs-human-insight-validating-quantitative-data-2026-pharma-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/ai-vs-human-insight-validating-quantitative-data-2026-pharma-research</guid>
  <pubDate>Wed, 25 Feb 2026 02:20:00 GMT</pubDate>
  <description>Why Data Validation Became a Board-Level Issue In 2026, quantitative studies in pharmaceutical and MedTech markets face a new integrity threat:.</description>
</item>
<item>
  <title>Strategy 2026: Pharmaceutical Healthcare Market Research in KSA and UAE</title>
  <link>https://www.bionixus.com/blog/pharmaceutical-healthcare-market-research-gcc</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmaceutical-healthcare-market-research-gcc</guid>
  <pubDate>Mon, 23 Feb 2026 08:00:00 GMT</pubDate>
  <description>As Saudi Arabia and the UAE accelerate their Vision 2030 and Dubai Economic Agenda (D33) goals, &apos;pharmaceutical healthcare market research&apos; has become.</description>
</item>
<item>
  <title>Hospital Market Research: Strategic Sourcing in the Digital Age</title>
  <link>https://www.bionixus.com/blog/hospital-market-research</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/hospital-market-research</guid>
  <pubDate>Sun, 15 Feb 2026 09:00:00 GMT</pubDate>
  <description>The modernization of European hospital infrastructure is creating a $12B opportunity for medtech. Hospital market research is the key to understanding proc</description>
</item>
<item>
  <title>Unlocking Growth: Healthcare Market Research Europe 2026</title>
  <link>https://www.bionixus.com/blog/healthcare-market-research-europe-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/healthcare-market-research-europe-2026</guid>
  <pubDate>Sun, 15 Feb 2026 09:00:00 GMT</pubDate>
  <description>European healthcare systems are navigating a critical shift toward value-based care and AI integration. This article explores how healthcare market researc</description>
</item>
<item>
  <title>Kuwait Healthcare Market: Key Trends for 2026</title>
  <link>https://www.bionixus.com/blog/kuwait-healthcare-market-trends-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/kuwait-healthcare-market-trends-2026</guid>
  <pubDate>Sun, 15 Feb 2026 01:16:58 GMT</pubDate>
  <description>Explore the key trends shaping Kuwait&apos;s healthcare market in 2026, from Vision 2035 investments and digital health transformation to private sector growth</description>
</item>
<item>
  <title>Deutsche Pharmaunternehmen 2026: Therapiegebiete und Pipeline-Updates im Überblick</title>
  <link>https://www.bionixus.com/blog/deutsche-pharmaunternehmen-2026-pipeline-updates</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/deutsche-pharmaunternehmen-2026-pipeline-updates</guid>
  <pubDate>Sat, 14 Feb 2026 21:00:00 GMT</pubDate>
  <description>BioNTech rückt mit 15 Phase-3-Studien und mRNA-Immuntherapien in die Onkologie-Spitzenliga vor. Bayer treibt nach fünf pivotalen Zulassungen den Konzernumb</description>
</item>
<item>
  <title>Gesundheitsmarkt Deutschland 2026: Krankenhausreform, Digitalisierung und Pharma-Trends im Überblick</title>
  <link>https://www.bionixus.com/blog/gesundheitsmarkt-deutschland-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/gesundheitsmarkt-deutschland-2026</guid>
  <pubDate>Sat, 14 Feb 2026 20:00:00 GMT</pubDate>
  <description>Deutschland steht vor den umfassendsten Gesundheitsreformen seit Jahrzehnten: ein €50-Milliarden-Transformationsfonds für Krankenhäuser, die verpflichtende</description>
</item>
<item>
  <title>Healthcare Overview: The Qatari Market in 2026, Precision Medicine, Pharma Growth, and the Health for All Strategy</title>
  <link>https://www.bionixus.com/blog/healthcare-overview-qatar-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/healthcare-overview-qatar-market-2026</guid>
  <pubDate>Sat, 14 Feb 2026 19:00:00 GMT</pubDate>
  <description>Qatar is sequencing 350,000 genomes, funding CAR-T cell production at Sidra Medicine, and executing a National Health Strategy targeting 82.6-year life.</description>
</item>
<item>
  <title>Healthcare Overview: The Kuwaiti Market in 2026, Vision 2035, Pharma Manufacturing, and Digital Transformation</title>
  <link>https://www.bionixus.com/blog/healthcare-overview-kuwait-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/healthcare-overview-kuwait-market-2026</guid>
  <pubDate>Sat, 14 Feb 2026 18:00:00 GMT</pubDate>
  <description>Kuwait healthcare 2026: MOH hospitals, pharma distributors, tender policy &amp; physician insight for Vision 2035. BioNixus market research guide.</description>
</item>
<item>
  <title>Healthcare Overview: The Egyptian Market in 2026, Pharma, Policy, and Digital Transformation</title>
  <link>https://www.bionixus.com/blog/healthcare-overview-egypt-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/healthcare-overview-egypt-market-2026</guid>
  <pubDate>Sat, 14 Feb 2026 16:00:00 GMT</pubDate>
  <description>Cairo hospitals healthcare 2023, 2026: Kasr Al-Ainy, Cleopatra, Saudi German Cairo, EDA pharma access, UHI payer trends, BioNixus Egypt research.</description>
</item>
<item>
  <title>The State of Oncology in the UAE: What 2026&apos;s Milestones Mean for Cancer Care</title>
  <link>https://www.bionixus.com/blog/oncology-uae-2026-cancer-care-outlook</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/oncology-uae-2026-cancer-care-outlook</guid>
  <pubDate>Sat, 14 Feb 2026 14:00:00 GMT</pubDate>
  <description>From a $392 million oncology drug market to locally manufactured cancer therapies, Dubai&apos;s first integrated cancer hospital, and a $200 million precision.</description>
</item>
<item>
  <title>Rare Disease and Orphan Drug Access in Saudi Arabia: What SFDA&apos;s 2026 Designations Mean for Patients</title>
  <link>https://www.bionixus.com/blog/rare-disease-orphan-drug-saudi-arabia-sfda-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/rare-disease-orphan-drug-saudi-arabia-sfda-2026</guid>
  <pubDate>Sat, 14 Feb 2026 12:00:00 GMT</pubDate>
  <description>Saudi Arabia&apos;s SFDA granted landmark orphan drug designations in January 2026, signaling accelerated access to breakthrough therapies for rare disease pati</description>
</item>
<item>
  <title>中国医疗健康市场概览2026：政策改革、创新药物与AI医疗的全景分析</title>
  <link>https://www.bionixus.com/blog/healthcare-overview-china-market-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/healthcare-overview-china-market-2026</guid>
  <pubDate>Sat, 14 Feb 2026 12:00:00 GMT</pubDate>
  <description>深入解析中国2026年医疗健康市场全景，涵盖医保改革、创新药出海、AI医疗商业化、生物药增长及老龄化带来的医疗需求变革。为制药企业、投资者和行业从业者提供全面的市场洞察。. Read the guide. BioNixus pharmaceutical and healthcare market</description>
</item>
<item>
  <title>UK Pharmaceutical Market Research Update</title>
  <link>https://www.bionixus.com/blog/pharmaceutical-market-research-uk-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmaceutical-market-research-uk-2026</guid>
  <pubDate>Sat, 14 Feb 2026 10:00:00 GMT</pubDate>
  <description>The UK life sciences sector is undergoing a transformation driven by multi-omics and AI-integrated drug discovery. Effective pharmaceutical market research</description>
</item>
<item>
  <title>SFDA Approval of Qfitlia: Saudi Arabia Pharmaceutical Market</title>
  <link>https://www.bionixus.com/blog/sfda-approval-qfitlia-saudi-arabia-pharmaceutical-market</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/sfda-approval-qfitlia-saudi-arabia-pharmaceutical-market</guid>
  <pubDate>Fri, 13 Feb 2026 08:00:00 GMT</pubDate>
  <description>The SFDA&apos;s recent approval of Qfitlia for Hemophilia A and B marks a significant milestone in the Saudi Arabia pharmaceutical market. This siRNA-based ther</description>
</item>
<item>
  <title>The 2026 Physician Sentiment Index: Redefining Healthcare Market Research</title>
  <link>https://www.bionixus.com/blog/physician-surveys-healthcare-digital-health-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/physician-surveys-healthcare-digital-health-2026</guid>
  <pubDate>Sun, 08 Feb 2026 11:00:00 GMT</pubDate>
  <description>Original physician surveys healthcare data reveals a critical &apos;trust gap&apos; in AI diagnostics and telehealth integration. This report leverages healthcare.</description>
</item>
<item>
  <title>BioNixus FDA Alert: The 2026 GLP-1 Obesity Market Crackdown</title>
  <link>https://www.bionixus.com/blog/fda-update-glp-1-obesity-market-crackdown-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/fda-update-glp-1-obesity-market-crackdown-2026</guid>
  <pubDate>Sat, 07 Feb 2026 10:00:00 GMT</pubDate>
  <description>The FDA&apos;s February 2026 statement targeting non-FDA-approved GLP-1 drugs has sent shockwaves through the metabolic health sector. This update analyzes.</description>
</item>
<item>
  <title>The New EMEA JCA Market Access Update: What You Need to Know</title>
  <link>https://www.bionixus.com/blog/emea-jca-market-access-update-2026</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/emea-jca-market-access-update-2026</guid>
  <pubDate>Sat, 07 Feb 2026 09:00:00 GMT</pubDate>
  <description>The rollout of the EU Joint Clinical Assessment (JCA) in 2026 is the single most disruptive event in EMEA market access history. This update breaks down.</description>
</item>
<item>
  <title>Optimizing Physician Surveys Healthcare: Data Quality in 2026</title>
  <link>https://www.bionixus.com/blog/physician-surveys-healthcare</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/physician-surveys-healthcare</guid>
  <pubDate>Thu, 05 Feb 2026 14:00:00 GMT</pubDate>
  <description>Physician engagement is reaching a saturation point. Discover how modern physician surveys healthcare strategies leverage behavioral economics and rapid-re</description>
</item>
<item>
  <title>Pharmaceutical Market Entry in Saudi Arabia: A Strategic Guide for 2026</title>
  <link>https://www.bionixus.com/blog/pharmaceutical-market-entry-saudi-arabia-2026-guide</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmaceutical-market-entry-saudi-arabia-2026-guide</guid>
  <pubDate>Wed, 04 Feb 2026 13:54:03 GMT</pubDate>
  <description>Saudi pharma market entry 2026: SFDA registration, Vision 2030 incentives &amp; proven launch steps. Practical playbook from BioNixus research.</description>
</item>
<item>
  <title>UAE Healthcare Market: Trends &amp; Opportunities 2025</title>
  <link>https://www.bionixus.com/blog/uae-healthcare-market-trends-2025</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/uae-healthcare-market-trends-2025</guid>
  <pubDate>Wed, 04 Feb 2026 12:17:52 GMT</pubDate>
  <description>UAE healthcare trends: Dubai &amp; Abu Dhabi pharma demand, MOHAP/DHA dynamics, payer signals &amp; growth angles for pharma and medtech.</description>
</item>
<item>
  <title>Pharmacoeconomics in GCC Markets: A Practical Guide</title>
  <link>https://www.bionixus.com/blog/pharmacoeconomics-gcc-practical-guide</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/pharmacoeconomics-gcc-practical-guide</guid>
  <pubDate>Wed, 04 Feb 2026 12:17:45 GMT</pubDate>
  <description>Pharmacoeconomics across UAE, Saudi Arabia &amp; Kuwait: HTA frameworks, evidence needs &amp; practical HEOR steps for pharma access teams.</description>
</item>
<item>
  <title>Quantitative Market Research and Market Access Impact</title>
  <link>https://www.bionixus.com/blog/quantitative-market-research-and-market-access-impact</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/quantitative-market-research-and-market-access-impact</guid>
  <pubDate>Tue, 03 Feb 2026 00:30:00 GMT</pubDate>
  <description>How quantitative market research supports pharmaceutical market access, payer evidence, physician surveys, and launch readiness across GCC and global.</description>
</item>
<item>
  <title>Why Market Research Is Essential for Pharmaceutical Market Access in the UAE</title>
  <link>https://www.bionixus.com/blog/market-research-pharmaceutical-market-access-uae</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/market-research-pharmaceutical-market-access-uae</guid>
  <pubDate>Wed, 05 Feb 2025 10:00:00 GMT</pubDate>
  <description>Pharmaceutical market access in the UAE, reimbursement, formulary listing, and physician adoption, depends on evidence and stakeholder alignment. Market rese</description>
</item>
<item>
  <title>Healthcare Market Research in UAE: The Definitive Guide for Pharmaceutical Companies (2025)</title>
  <link>https://www.bionixus.com/blog/healthcare-market-research-uae-guide-2025</link>
  <guid isPermaLink="true">https://www.bionixus.com/blog/healthcare-market-research-uae-guide-2025</guid>
  <pubDate>Tue, 04 Feb 2025 10:00:00 GMT</pubDate>
  <description>The UAE healthcare market, valued at USD 22 billion in 2024, represents one of the fastest-growing pharmaceutical markets in the Middle East. This comprehe</description>
</item>
  </channel>
</rss>
